Shriya Narendra Shet Shirodkar

Shriya Narendra Shet Shirodkar

Auto-generated profile, based on publicly available information

Shriya Narendra Shet Shirodkar

Department of Nephrology Kasturba Medical College, Manipal Academy of Higher Education Manipal Karnataka India

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2025 in Clinical and Translational Science
Verified
Journal Article
Open access
DRDipali Raju
Dipali Raju
SPSwathi Prabhu
Swathi Prabhu
AMAnjal Maria
Anjal Maria
SSShriya Narendra Shet Shirodkar
Shriya Narendra Shet Shirodkar
RDRama Rao Damerla
Rama Rao Damerla
NKNaveena AN Kumar
Naveena AN Kumar
Gastric Signet Ring Cell Carcinoma (GSRCC) is an increasingly recognized subtype of gastric cancer, particularly prevalent in South Asian populations and regions within India. This carcinoma is distinguished by its abundant cytoplasmic mucinous cells and aggressive clinical behavior, often affecting younger individuals and leading to a poor prognosis due to its advanced‐stage presentation and resistance to standard treatments. A critical factor in its progression is the tumor's uniquely immunosuppressive and stromal‐rich microenvironment, characterized by dysfunctional immune infiltrates, activation of cancer‐associated fibroblasts, extracellular matrix remodeling, and complement cascade dysfunction. Recent research has highlighted the significance of key biomarkers, including MSMB, AGR2, CLDN18.2, and notably GRIN2D, which play roles in tumor angiogenesis, immune evasion, and metabolic reprogramming. The interaction of these elements contributes to therapeutic resistance and immune escape, thereby reducing the effectiveness of chemotherapy and checkpoint inhibitor immunotherapies. Innovative strategies that integrate stromal‐targeting agents, complement modulators, anti‐CLDN18.2 antibodies, and novel GRIN2D‐targeted therapies, along with precision molecular profiling, offer potential for enhancing patient outcomes. Tailored approaches that incorporate early detection and dynamic biomarker monitoring may ultimately transform GSRCC management toward personalized, evidence‐based therapies and prevention.